KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Work In Process (2018 - 2025)

Historic Work In Process for Acadia Pharmaceuticals (ACAD) over the last 8 years, with Q3 2025 value amounting to $76.9 million.

  • Acadia Pharmaceuticals' Work In Process rose 19918.67% to $76.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.9 million, marking a year-over-year increase of 19918.67%. This contributed to the annual value of $69.7 million for FY2024, which is 140693.6% up from last year.
  • Acadia Pharmaceuticals' Work In Process amounted to $76.9 million in Q3 2025, which was up 19918.67% from $84.4 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Work In Process registered a high of $84.4 million during Q2 2025, and its lowest value of $4.6 million during Q3 2023.
  • Moreover, its 5-year median value for Work In Process was $6.7 million (2021), whereas its average is $22.5 million.
  • Its Work In Process has fluctuated over the past 5 years, first crashed by 2723.51% in 2022, then skyrocketed by 140693.6% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Work In Process (Quarter) stood at $6.8 million in 2021, then dropped by 27.24% to $4.9 million in 2022, then fell by 6.01% to $4.6 million in 2023, then surged by 1406.94% to $69.7 million in 2024, then increased by 10.25% to $76.9 million in 2025.
  • Its Work In Process was $76.9 million in Q3 2025, compared to $84.4 million in Q2 2025 and $80.0 million in Q1 2025.